Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 7/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19156078 | 0.88 | MT-CO2 (0.43) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18499737 | 0.85 | KMT2A (0.46) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20042025 | 0.84 | MT-CO2 (0.45) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19975822 | 0.84 | ADAM17 (0.56) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL21727101 | 0.82 | KMT2A (0.45) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18626054 | 0.82 | KMT2A (0.55) | KMT2AALDH1A1TP53MAPTHTT | |
| SCHEMBL18626051 | 0.82 | GAA (0.45) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18888421 | 0.81 | MT-CO2 (0.43) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19231279 | 0.80 | MT-CO2 (0.41) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19231281 | 0.80 | MT-CO2 (0.41) | MT-CO2ALOX5KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-11-05 | — | — | US | disclosed |
| US-20200054761-A1 | METHODS AND COMPOSITION FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS | THOMAS JEFFERSON UNIVERSITY (US) | 2020-02-20 | — | — | US | disclosed |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10329352-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190015524-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20180125994-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | ADC THERAPEUTICS SA (CH) | 2018-05-10 | — | — | US | disclosed |
| US-20170298137-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2017-10-19 | — | — | US | disclosed |
| US-9707301-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9567340-B2 | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases | MEDIMMUNE LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298137-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | DRD2, DRD3, SBDS | MT-CO2 3761/4885ALOX5 3775/4885KMT2A 2010/4885 |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD79B, BCL6B, BCL6 | MT-CO2 4804/4885ALOX5 4693/4885KMT2A 628/4885 |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | QDPR, SBDS, DNPEP | MT-CO2 4193/4885ALOX5 3467/4885KMT2A 2477/4885 |
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | AXL, TYRO3, FLT3 | MT-CO2 4853/4885ALOX5 4483/4885KMT2A 776/4885 |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | MT-CO2 4706/4885ALOX5 4847/4885KMT2A 1144/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | MT-CO2 2678/4885ALOX5 4221/4885KMT2A 1237/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | MT-CO2 4804/4885ALOX5 4693/4885KMT2A 628/4885 |
| US-20190015524-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD4, CD47, IL2RA | MT-CO2 2238/4885ALOX5 3694/4885KMT2A 809/4885 |
| US-20200054761-A1 | METHODS AND COMPOSITION FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS | MSR1, CD209, CD14 | MT-CO2 4819/4885ALOX5 1940/4885KMT2A 2580/4885 |
| US-20180125994-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | FOLH1, PSMA2, DNPEP | MT-CO2 3873/4885ALOX5 4775/4885KMT2A 844/4885 |
| US-10329352-B2 | Pyrrolobenzodiazepines and targeted conjugates | DRD2, DRD3, SBDS | MT-CO2 3761/4885ALOX5 3775/4885KMT2A 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.